Fellow Investor,
If you’re looking for a way to make money in the markets without investing in volatile AI stocks…
Or plunking your hard-earned money into complicated crypto currencies…
Then you’re going to love my e-book called “How To Master The Retirement Trade.”
Because it reveals how to use a little-know strategy I’ve developed to pinpoint – and profit – from trades that can play out in as little as 11 hours.
You can reserve your copy here now….
Just be sure to do it now.
To prevent the trades I release from getting overcrowded with profit-hungry investors…
I’m strictly limiting the number of people who get copies of this guide.
To your investing success,
Dave Aquino
Partner, Head of Options Trading
Base Camp Trading
Why Wall Street Is Backing These 3 Comeback Stocks
Written by Nathan Reiff. Published 10/28/2025.
Key Points
- Stocks staging a comeback rally can reward investors willing to take a risk with significant gains.
- Analysts have flagged companies including The Trade Desk, Summit Therapeutics, and Sprouts Farmers Market as having sizable upside potential after earlier declines.
- These companies face external challenges of various kinds, but offer compelling product lineups or pipelines and fundamentals.
A company's comeback can present a significant opportunity for investors. When a stock has lost a sizable portion of its value, many investors prefer caution unless there's a clear sign the firm's fortunes are reversing. If a rally materializes, investors who bought in the dip could see the biggest gains.
Wall Street analysts say the three companies below—The Trade Desk Inc. (NASDAQ: TTD), Summit Therapeutics PLC (NASDAQ: SMMT), and Sprouts Farmers Market Inc. (NASDAQ: SFM)—each representing a different industry, could be poised for such a comeback. Shares of each have fallen in recent months, but investors with a higher tolerance for risk may find compelling opportunities.
External Threats Impact The Trade Desk, But Platform Relaunch Could Boost Interest
Buy the stock when it touches this ONE line on the chart (Ad)
In 2008, I went on CNBC and warned of a huge crash in the market.
Get this free, 43-minute training on the next page. Just put in your email.Ad tech giant The Trade Desk is down more than 54% year-to-date after missing its EPS estimate for the latest quarter by $0.24. The company faces growing competition from tech rivals—not all of it from traditional ad platforms—including Amazon.com Inc. (NASDAQ: AMZN), which recently offered potential advertisers free use of its demand-side platform (DSP) to test against competitors' products. This directly pressures TTD, which lost its exclusive partnership with Walmart Inc. (NYSE: WMT) over the summer.
There are reasons for cautious optimism. Despite recent slowing, revenue grew 19% year-over-year in the latest quarter, and TTD remains a leading ad tech firm even as rivals emerge.
Some revenue pressure stems from user pushback on its Kokai platform, but the company announced a broad set of enhancements in September that could renew interest. One feature in particular—Deal Desk, launched earlier in the year—fills an important gap as a deal-optimization and pacing tool.
Analysts are mixed on TTD, but a majority (21 of 37) rate the stock a Buy. TTD's consensus price target is just over $84, roughly 58% above its current trading level.
Summit's Pipeline Is Promising, But Cash Position Is a Risk
Clinical-stage biotech firm Summit Therapeutics is known for ridinilazole, a candidate for treating Clostridioides difficile infections. The company remains unprofitable and posted wider-than-expected losses per share in its third quarter of 2025. Summit's largest immediate hurdle is its cash runway: it ended the latest quarter with less than $239 million in cash, while rising operating expenses are quickly depleting reserves.
Executives have suggested a potential equity financing or at-the-market offering to finance ongoing trials. That route would dilute existing shareholders, and SMMT shares have fallen nearly 20% over the past six months amid those concerns.
Still, the pipeline is encouraging if Summit can shore up funding. The company plans to submit a biologics license application related to Ivonescimab, a potential lung-cancer therapy, this quarter, and the drug candidate's Phase III trial is set to expand—a positive signal for eventual marketability.
Twelve of 18 analysts rate SMMT shares a Buy, and the consensus price target of $31.14 implies nearly 60% upside.
Strong Fundamentals Could Help Sprouts to Trend Higher
Organic specialty grocer Sprouts Farmers Market has seen shares decline almost 20% this year amid inflation and softer consumer sentiment. However, the company's latest earnings were encouraging: it beat on both the top and bottom lines, with sales up 17% year-over-year driven by strong e-commerce growth. Management raised full-year sales and other forecasts at the time.
Sprouts has returned capital to shareholders, deploying more than $400 million in operating cash flow as of midyear, including $292 million in share repurchases.
The company's focus on more affluent customers and regions may help insulate it from rising grocery prices and tariff pressure. Analysts appear to agree—10 of 15 rate SFM a Buy, and the consensus outlook implies about 51% upside potential.
This message is a sponsored message sent on behalf of Base Camp Trading, a third-party advertiser of The Early Bird and MarketBeat.
This promotional message is sent on behalf of Base Camp Trading, located at 5540 Centerview Drive, Suite 204, Raleigh, NC 27606. If you no longer wish to receive promotional emails from Base Camp Trading, please unsubscribe here with the "optout" in the subject line.
If you need assistance with your subscription, don't hesitate to contact our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2025 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States of America..